2/2
03:18 pm
guts
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts [Seeking Alpha]
Low
Report
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts [Seeking Alpha]
1/30
11:46 am
guts
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
Low
Report
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
1/30
01:42 am
guts
Fractyl Health (GUTS) Tests Whether Revita Can Redefine Post-GLP-1 Weight Maintenance Economics [Yahoo! Finance]
High
Report
Fractyl Health (GUTS) Tests Whether Revita Can Redefine Post-GLP-1 Weight Maintenance Economics [Yahoo! Finance]
1/29
07:02 pm
guts
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation [Yahoo! Finance]
High
Report
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation [Yahoo! Finance]
1/29
05:01 pm
guts
Fractyl Health (NASDAQ:GUTS) was downgraded by analysts at Morgan Stanley to a "cautious" rating.
High
Report
Fractyl Health (NASDAQ:GUTS) was downgraded by analysts at Morgan Stanley to a "cautious" rating.
1/29
04:16 pm
guts
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
High
Report
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
1/6
07:00 am
guts
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
Medium
Report
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
1/5
07:13 am
guts
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category [Yahoo! Finance]
Medium
Report
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category [Yahoo! Finance]
1/5
07:00 am
guts
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
Medium
Report
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
1/3
06:28 am
guts
Analysts Keep Buy Ratings on Fractyl Health (GUTS) [Yahoo! Finance]
Medium
Report
Analysts Keep Buy Ratings on Fractyl Health (GUTS) [Yahoo! Finance]
12/31
11:21 am
guts
Fractyl Health's REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use [Yahoo! Finance]
Low
Report
Fractyl Health's REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use [Yahoo! Finance]
12/19
07:19 am
guts
Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Medium
Report
Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
12/15
05:56 pm
guts
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones [Yahoo! Finance]
Neutral
Report
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones [Yahoo! Finance]
12/15
05:45 pm
guts
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Neutral
Report
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
12/2
12:39 pm
guts
Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/2
07:00 am
guts
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
High
Report
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
12/1
07:00 am
guts
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
11/21
01:43 pm
guts
Fractyl Health (NASDAQ:GUTS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Fractyl Health (NASDAQ:GUTS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
11/12
08:27 pm
guts
Fractyl Health outlines 2026 Revita pivotal data and PMA submission targets as clinical momentum accelerates [Seeking Alpha]
Medium
Report
Fractyl Health outlines 2026 Revita pivotal data and PMA submission targets as clinical momentum accelerates [Seeking Alpha]
11/12
04:32 pm
guts
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 [Yahoo! Finance]
Low
Report
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 [Yahoo! Finance]
11/12
04:05 pm
guts
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Low
Report
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027